The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Comparative Efficacy and Safety of 4 Randomized Regimens to Treat Early Pseudomonas aeruginosa Infection in Children With Cystic Fibrosis
Open accessAbstract
OBJECTIVE: To investigate the efficacy and safety of 4 antipseudomonal treatments in children with cystic fibrosis with recently acquired Pseudomonas aeruginosa infection. DESIGN: Randomized controlled trial. SETTING: Multicenter trial in the United States. PARTICIPANTS: Three hundred four children with cystic fibrosis aged 1 to 12 years within 6 months of P aeruginosa detection. INTERVENTIONS: Participants were randomized to 1 of 4 antibiotic regimens for 18 months (six 12-week quarters) between December 2004 and June 2009. Participants randomized to cycled therapy received tobramycin inhalation solution (300 mg twice a day) for 28 days, with oral ciprofloxacin (15-20 mg/kg twice a day) or oral placebo for 14 days every quarter, while participants randomized to culture-based therapy received the same treatments only during quarters with positive P aeruginosa cultures. MAIN OUTCOME MEASURES: The primary end points were time to pulmonary exacerbation requiring intravenous antibiotics and proportion of P aeruginosa -positive cultures. RESULTS: The intention-to-treat analysis included 304 participants. There was no interaction between treatments. There were no statistically significant differences in exacerbation rates between cycled and culture-based groups (hazard ratio, 0.95; 95% confidence interval [CI], 0.54-1.66) or ciprofloxacin and placebo (hazard ratio, 1.45; 95% CI, 0.82-2.54). The odds ratios of P aeruginosa- positive culture comparing the cycled vs culture-based group were 0.78 (95% CI, 0.49-1.23) and 1.10 (95% CI, 0.71-1.71) comparing ciprofloxacin vs placebo. Adverse events were similar across groups. CONCLUSIONS: No difference in the rate of exacerbation or prevalence of P aeruginosa positivity was detected between cycled and culture-based therapies. Adding ciprofloxacin produced no benefits. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT00097773.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bacterial Biofilms: A Common Cause of Persistent Infections
Costerton, J. W., Stewart, P. S., & Greenberg, E. P. (1999) · Science · doi:10.1126/science.284.5418.1318 · Cited by 12,167
Saiman, L., Marshall, B. C., Mayer-Hamblett, N., Burns, J. L., Quittner, A. L., Cibene, D. A., Coquillette, S., Fieberg, A. Y., Accurso, F. J., Campbell III, P. W., et al. (2003) · JAMA · doi:10.1001/jama.290.13.1749 · Cited by 958
Self-citation
Cited by
The Epidemiology and Pathogenesis and Treatment of Pseudomonas aeruginosa Infections: An Update
Reynolds, D., & Kollef, M. (2021) · Drugs · doi:10.1007/s40265-021-01635-6 · Cited by 721
Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis
Langton Hewer, S. C., & Smyth, A. R. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004197.pub4 · Cited by 324
Mogayzel, P. J., Naureckas, E. T., Robinson, K. A., Brady, C., Guill, M., Lahiri, T., Lubsch, L., Matsui, J., Oermann, C. M., Ratjen, F., et al. (2014) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201404-166oc · Cited by 269
Self-citationCystic Fibrosis Lung Disease: An Overview
Turcios, N. L. (2020) · Respiratory Care · doi:10.4187/respcare.06697 · Cited by 217
Inhaled anti-pseudomonal antibiotics for long-term therapy in cystic fibrosis
Smith, S., Rowbotham, N. J., & Regan, K. H. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001021.pub3 · Cited by 92
Metadata
- Authors
- Treggiari, M. M., Retsch-Bogart, G., Mayer-Hamblett, N., Khan, U., Kulich, M., Kronmal, R., Williams, J., Hiatt, P., Gibson, R. L., Spencer, T., Orenstein, D., Chatfield, B. A., Froh, D. K., Burns, J. L., Rosenfeld, M., Ramsey, B. W., & for the Early Pseudomonas Infection Control (EPIC) Investigators
- Venue
- Archives of Pediatrics & Adolescent Medicine
- Publisher
- American Medical Association (AMA)
- Published
- 2011-09-01
- Volume
- 165
- Issue
- 9
- Pages
- 847
- ISSN
- 1072-4710 (ISSN-L)
- OpenAlex
- W2110549473
- Cited by
- 215
- References
- 2
- FWCI
- 16.83
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Comparative Efficacy and Safety of 4 Randomized Regimens to Treat Early Pseudomonas aeruginosa Infection in Children With Cystic Fibrosis. https://app.cochat.ai/papers/10.1001/archpediatrics.2011.136
- The paper
- Treggiari, M. M., Retsch-Bogart, G., Mayer-Hamblett, N., Khan, U., Kulich, M., Kronmal, R., Williams, J., Hiatt, P., Gibson, R. L., Spencer, T., Orenstein, D., Chatfield, B. A., Froh, D. K., Burns, J. L., Rosenfeld, M., Ramsey, B. W., & for the Early Pseudomonas Infection Control (EPIC) Investigators. (2011). Comparative Efficacy and Safety of 4 Randomized Regimens to Treat Early Pseudomonas aeruginosa Infection in Children With Cystic Fibrosis. Archives of Pediatrics & Adolescent Medicine. https://doi.org/10.1001/archpediatrics.2011.136
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.